Cargando…

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a life‐threatening disease characterized by vasoconstriction and remodeling of the pulmonary vessels. Risk stratification in PAH could potentially be improved by including novel biomarkers related to PAH pathobiology. We aimed to investigate the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arvidsson, Mattias, Ahmed, Abdulla, Säleby, Joanna, Hesselstrand, Roger, Rådegran, Göran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053005/ https://www.ncbi.nlm.nih.gov/pubmed/35506077 http://dx.doi.org/10.1002/pul2.12041

Ejemplares similares

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Prolargin and matrix metalloproteinase‐2 in heart failure after heart transplantation and their association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2019)

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2019)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
por: Kylhammar, David, et al.
Publicado: (2021)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Elevated plasma tyrosine kinases VEGF-D and HER4 in heart failure patients decrease after heart transplantation in association with improved haemodynamics
por: Ahmed, Salaheldin, et al.
Publicado: (2020)

Underfilling decreases left ventricular function in pulmonary arterial hypertension
por: Sjögren, Hannah, et al.
Publicado: (2021)

Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension
por: Lindholm, Anthony, et al.
Publicado: (2022)

Longitudinal changes in risk status in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se
por: Lindholm, Anthony, et al.
Publicado: (2019)

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre‐capillary pulmonary hypertension
por: Bredfelt, Anna, et al.
Publicado: (2018)

Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics
por: Ahmed, Abdulla, et al.
Publicado: (2020)

Elevated plasma WIF‐1 levels are associated with worse prognosis in heart failure with pulmonary hypertension
por: Kania, Kriss, et al.
Publicado: (2022)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension
por: Ahmed, Salaheldin, et al.
Publicado: (2021)

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension
por: Engel Sällberg, Adam, et al.
Publicado: (2023)

Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2018)

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
por: Hjalmarsson, Clara, et al.
Publicado: (2021)

Right atrial volume measured by cardiac magnetic resonance correlates with NT-ProBNP and invasive right atrial pressure in pulmonary hypertension, with and without systemic sclerosis
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Increased biventricular hemodynamic forces in precapillary pulmonary hypertension
por: Pola, Karin, et al.
Publicado: (2022)

Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction
por: Sandqvist, Anna, et al.
Publicado: (2017)

Pulmonary blood density in systemic sclerosis – a novel non-invasive measure of pulmonary arterial hypertension?
por: Kanski, Mikael, et al.
Publicado: (2009)

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2022)

Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf’s Skin?
por: Goncharova, Elena A., et al.
Publicado: (2021)

Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2016)

Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis
por: Valente, Flavia Mariana, et al.
Publicado: (2020)

Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation
por: Lundgren, Jakob, et al.
Publicado: (2015)

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016
por: Kjellström, Barbro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qf6ln7prrq94q4pj8st4emj876